HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82% Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the C ...